DENVER--(BUSINESS WIRE)--TriSalus™ Life Sciences announced the election of Diane Parks and Yongxin Han to its Board of Directors, effective immediately.
The appointment of two new members of the company’s board of directors further advances the transformation into an oncology platform and brings expertise in the development and commercialization of drug and drug delivery technology.
Ms. Parks joins the TriSalus board with more than 30 years of expertise across the biotech, pharmaceutical, and advertising industries. She’s held executive roles at Kite Pharma Inc, Pharmacyclics, Amgen, and Genentech, most recently serving as senior vice president, marketing and account management at Kite Pharma Inc. Ms. Parks is credited with successfully leading the launch of the first-ever CAR-T therapy, YESCARTA.
She holds a Master of Business Administration degree from Georgia State University and received her Bachelor of Arts degree from Kansas State University. Diane currently serves as a member of the Board for Calliditas Therapeutics, an early stage pharmaceutical company based in Stockholm, Sweden.
Yongxin Han, PhD
Dr. Yongxin Han has more than 20 years of U.S. pharmaceutical experience, having co-founded and served as General Manager of Chemizon Inc. and Centaurus BioPharma. His work includes delivering more than 14 investigational new drug applications for cancer treatment, including kinase inhibitors, small molecule immunotherapy agents, and tumor metabolism modulators. Dr. Han is a partner at Lapam Capital LLC, a professional RMB Venture Capital firm focused on the investment in innovative drug discovery, medical devices and diagnostic technologies in China. Lapam is recognized for innovation in drug discovery and development.
He holds a PhD in chemistry from University of Minnesota, a Master of Science degree from the Chinese Academy of Science; and a Bachelor of Science degree from Peking University.
“The composition of the board with the skills and expertise brought by Diane and Yongxin reflects the alignment of the leadership to the company’s strategy,” said Mats L. Wahlström, TriSalus Chairman. “We’re honored to add the depth of experience in oncology and drug delivery technology with the appointment of Diane and Yongxin,” added Wahlström.
“Advancing the integration of oncology delivery devices with therapeutics is central to improving outcomes for cancer patients,” said Mary Szela, president and CEO of TriSalus. We’re thrilled to add the depth of experience that Diane and Yongxin bring to our board as we accelerate the advancement of therapeutics and infusion delivery to facilitate market access for patients,” added Szela.
About TriSalus™ Life Sciences and PEDD™ Therapeutics Delivery to Solid Tumors
TriSalus™ Life Sciences is committed to transforming outcomes for patients with pancreatic cancer and other solid tumors. Our solution is bold: to integrate novel and proprietary therapeutics with the TriSalus Pressure-Enabled Drug Delivery™ (PEDD™) technology. It’s a comprehensive approach intended to improve treatment response and ultimately outcomes.
The PEDD platform increases drug concentration in the tumor by generating favorable pressure to overcome the infusion barriers of the tumor microenvironment. The integration of PEDD with chemotherapy, immunotherapy and other emerging therapies may improve treatment efficacy while reducing the toxicity challenges of traditional delivery methods.
Acknowledging that meaningful progress in this difficult-to-treat disease is not easy, we’re committed to transform the battle with pancreatic cancer through deep science, novel technology innovation and an absolute focus on the patient.
For more information, please visit www.trisaluslifesci.com.